ERBB2 and breast carcinoma: We next investigated SIRT7 expression on the basis of patients' different clinical pathological parameters, such as sample type (normal/primary tumor), breast cancer subclass (luminal, HER2+, and triple-negative), cancer stage (stages 1, 2, 3, and 4), and menopause status (premenopause, perimenopause, and postmenopause) using UALCAN database.